There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stereotaxis (STXS – Research Report) and Jasper Therapeutics (JSPR – Research Report) with bullish sentiments.
Stereotaxis (STXS)
TD Cowen analyst Josh Jennings maintained a Buy rating on Stereotaxis today and set a price target of $5.00. The company’s shares closed last Tuesday at $2.18.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.33, representing a 94.2% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Jasper Therapeutics (JSPR)
TD Cowen analyst Yaron Werber maintained a Buy rating on Jasper Therapeutics today. The company’s shares closed last Tuesday at $21.09.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jasper Therapeutics with a $67.00 average price target, representing a 225.1% upside. In a report issued on May 6, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $65.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STXS:
- Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
- Stereotaxis Reports 2024 First Quarter Financial Results
- STXS Earnings this Week: How Will it Perform?
- Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
- Stereotaxis management to meet with Lake Street
